Eledon Pharmaceuticals (ELDN) Capital Expenditures (2013 - 2016)

Eledon Pharmaceuticals (ELDN) has 4 years of Capital Expenditures data on file, last reported at -$3000.0 in Q4 2016.

• Quarterly Capital Expenditures fell 101.39% year-over-year to -$3000.0 in Q4 2016, while the trailing twelve-month figure through Dec 2016 was $9000.0 (down 98.41% YoY) and the FY2016 annual result came in at $9000.0, down 98.41% from the prior year.
• Capital Expenditures slipped to -$3000.0 in Q4 2016, from $2000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $216000.0 in Q4 2015 to a low of -$7000.0 in Q2 2016.
• A 4-year average of $50250.0 and a median of $9500.0 in 2014 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2015 — Capital Expenditures soared 2957.14% — and 2016, when it plunged 107.78%.
• Tracing ELDN's Capital Expenditures over 4 years: stood at $4000.0 in 2013, then jumped by 75.0% to $7000.0 in 2014, then soared by 2985.71% to $216000.0 in 2015, then sank by 101.39% to -$3000.0 in 2016.
• The last three Capital Expenditures figures came in at -$3000.0 (Q4 2016), $2000.0 (Q3 2016), and -$7000.0 (Q2 2016), per Business Quant data.